BMRA vs CODX vs QDEL vs OSUR vs HOLX

For growth investors, Hologic, Inc.

(HOLX) is the stronger pick with 1. 7% revenue growth year-over-year, versus -84. 1% for Co-Diagnostics, Inc. (CODX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Co-Diagnostics, Inc. (CODX) a "Hold" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.

0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -93. 3% for Biomerica, Inc. (BMRA). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus BMRA's -81. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 403% more volatile than HOLX relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hologic, Inc.

(HOLX) is pulling ahead at 1. 7% versus -84. 1% for Co-Diagnostics, Inc. (CODX). On earnings-per-share growth, the picture is similar: QuidelOrtho Corporation grew EPS 45. 4% year-over-year, compared to -500. 0% for Biomerica, Inc.. Over a 3-year CAGR, HOLX leads at -5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -75. 3% for Co-Diagnostics, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -50. 3% for CODX. At the gross margin level — before operating expenses — CODX leads at 64. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

0x forward P/E versus 17. 2x for Hologic, Inc. — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CODX: 137. 2% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), +124. 3% 10Y return). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.